Cervical Ripening in Premature Rupture of Membranes

NACompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

May 30, 2016

Study Completion Date

May 30, 2016

Conditions
PregnancyPremature Rupture of MembranesPreterm Premature Rupture of MembranesUnfavorable Cervix
Interventions
DRUG

Misoprostol

Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.

DRUG

Oxytocin

Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.

Trial Locations (1)

10461

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

Montefiore Medical Center

OTHER

NCT02314728 - Cervical Ripening in Premature Rupture of Membranes | Biotech Hunter | Biotech Hunter